Arbeitspapier
Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts
- Sprache
-
Englisch
- Erschienen in
-
Series: Working Paper ; No. 217
- Klassifikation
-
Wirtschaft
- Ereignis
-
Geistige Schöpfung
- (wer)
-
Philipson, Tomas J.
Berndt, Ernst R.
Gottschalk, Adrian H. B.
Sun, Eric
- Ereignis
-
Veröffentlichung
- (wer)
-
The University of Chicago, George J. Stigler Center for the Study of the Economy and the State
- (wo)
-
Chicago, IL
- (wann)
-
2007
- Handle
- Letzte Aktualisierung
-
10.03.2025, 11:44 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Arbeitspapier
Beteiligte
- Philipson, Tomas J.
- Berndt, Ernst R.
- Gottschalk, Adrian H. B.
- Sun, Eric
- The University of Chicago, George J. Stigler Center for the Study of the Economy and the State
Entstanden
- 2007
Ähnliche Objekte (12)
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
Additively manufactured medical products – the FDA perspective
The First FDA-Approved Antibody-Drug Conjugate
The effects of lobbying on the FDA’s recall classification
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
Additively manufactured medical products – the FDA perspective
The First FDA-Approved Antibody-Drug Conjugate
The effects of lobbying on the FDA’s recall classification
The FDA Changed Everything
A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches
The FDA initiatives for personalized medicine
Cost-Benefit Analysis and the Democratic Ideal
Cost-benefit analysis of the community patent
FDA
FDA
FDA
FDA
Additively manufactured medical products – the FDA perspective
The First FDA-Approved Antibody-Drug Conjugate